

# Maria Rosalia Pasca

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6657365/publications.pdf>

Version: 2024-02-01

74  
papers

4,377  
citations

101543

36  
h-index

114465

63  
g-index

80  
all docs

80  
docs citations

80  
times ranked

4582  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the Mycobacterium tuberculosis DprE1 Enzyme. International Journal of Molecular Sciences, 2022, 23, 771.	4.1	10
2	Nitric oxide-releasing compounds for the treatment of lung infections. Drug Discovery Today, 2021, 26, 542-550.	6.4	9
3	A Coumarin-Based Analogue of Thiacetazone as Dual Covalent Inhibitor and Potential Fluorescent Label of HadA in <i>Mycobacterium tuberculosis</i> . ACS Infectious Diseases, 2021, 7, 552-565.	3.8	13
4	Editorial: New Approaches Against Drug-Resistant M. tuberculosis. Frontiers in Microbiology, 2021, 12, 681420.	3.5	0
5	The Antimalarial Mefloquine Shows Activity against Mycobacterium abscessus, Inhibiting Mycolic Acid Metabolism. International Journal of Molecular Sciences, 2021, 22, 8533.	4.1	4
6	Gut Microbial Signatures in Sporadic and Hereditary Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 1312.	4.1	14
7	Design and Synthesis of Pyrano[3,2-b]indolones Showing Antimycobacterial Activity. ACS Infectious Diseases, 2021, 7, 88-100.	3.8	7
8	New Insights into the Mechanism of Action of the Thienopyrimidine Antitubercular Prodrug TP053. ACS Infectious Diseases, 2020, 6, 313-323.	3.8	11
9	First triclosan-based macrocyclic inhibitors of InhA enzyme. Bioorganic Chemistry, 2020, 95, 103498.	4.1	17
10	In vitro Study of Bedaquiline Resistance in Mycobacterium tuberculosis Multi-Drug Resistant Clinical Isolates. Frontiers in Microbiology, 2020, 11, 559469.	3.5	43
11	2-Aminooxazole as a Novel Privileged Scaffold in Antitubercular Medicinal Chemistry. ACS Medicinal Chemistry Letters, 2020, 11, 1435-1441.	2.8	18
12	Rv0579 Is Involved in the Resistance to the TP053 Antitubercular Prodrug. Frontiers in Microbiology, 2020, 11, 292.	3.5	5
13	Promiscuous Targets for Antitubercular Drug Discovery: The Paradigm of DprE1 and MmpL3. Applied Sciences (Switzerland), 2020, 10, 623.	2.5	44
14	Gut Microbiota Analysis in Postoperative Lynch Syndrome Patients. Frontiers in Microbiology, 2019, 10, 1746.	3.5	23
15	Mycobacterium abscessus, an Emerging and Worrisome Pathogen among Cystic Fibrosis Patients. International Journal of Molecular Sciences, 2019, 20, 5868.	4.1	84
16	Pyrazole and imidazo[1,2-b]pyrazole Derivatives as New Potential Antituberculosis Agents. Medicinal Chemistry, 2019, 15, 17-27.	1.5	17
17	A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and Pank. Scientific Reports, 2018, 8, 3187.	3.3	41
18	Shifts of Faecal Microbiota During Sporadic Colorectal Carcinogenesis. Scientific Reports, 2018, 8, 10329.	3.3	99

#	ARTICLE	IF	CITATIONS
19	The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase. Tuberculosis, 2018, 112, 98-109.	1.9	12
20	A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors. ACS Infectious Diseases, 2017, 3, 428-437.	3.8	34
21	New prodrugs against tuberculosis. Drug Discovery Today, 2017, 22, 519-525.	6.4	35
22	Mechanochemical Synthesis and Biological Evaluation of Novel Isoniazid Derivatives with Potent Antitubercular Activity. Molecules, 2017, 22, 1457.	3.8	71
23	Evaluation of the inhibitory activity of (aza)isoindolinone-type compounds: toward <i>in vitro</i> InhA action, <i>Mycobacterium tuberculosis</i> growth and mycolic acid biosynthesis. Chemical Biology and Drug Design, 2016, 88, 740-755.	3.2	1
24	Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and <i>Mycobacterium tuberculosis</i> . European Journal of Medicinal Chemistry, 2016, 123, 462-475.	5.5	33
25	Triazolophthalazines: Easily Accessible Compounds with Potent Antitubercular Activity. ChemMedChem, 2016, 11, 1078-1089.	3.2	12
26	Iron Acquisition Pathways as Targets for Antitubercular Drugs. Current Medicinal Chemistry, 2016, 23, 4009-4026.	2.4	35
27	New and Old Hot Drug Targets in Tuberculosis. Current Medicinal Chemistry, 2016, 23, 3813-3846.	2.4	26
28	TOWARDS NEW ANTITUBERCULAR DRUGS. Istituto Lombardo - Accademia Di Scienze E Lettere - Rendiconti Di Scienze, 2015, , .	0.0	0
29	The Redox State Regulates the Conformation of Rv2466c to Activate the Antitubercular Prodrug TP053. Journal of Biological Chemistry, 2015, 290, 31077-31089.	3.4	17
30	Pyridine-3,4-dicarboximide as starting material for the total synthesis of the natural product eupolauramine and its isomer iso-eupolauramine endowed with anti-tubercular activities. Tetrahedron, 2015, 71, 1555-1559.	1.9	8
31	Thiophenecarboxamide Derivatives Activated by EthA Kill <i>Mycobacterium tuberculosis</i> by Inhibiting the CTP Synthetase PyrG. Chemistry and Biology, 2015, 22, 917-927.	6.0	72
32	Design, synthesis and evaluation of new GEQ derivatives as inhibitors of InhA enzyme and <i>Mycobacterium tuberculosis</i> growth. European Journal of Medicinal Chemistry, 2015, 101, 218-235.	5.5	43
33	2-Carboxyquinoxalines Kill <i>Mycobacterium tuberculosis</i> through Noncovalent Inhibition of DprE1. ACS Chemical Biology, 2015, 10, 705-714.	3.4	116
34	Synthesis and evaluation of 1 <sup>2</sup> -hydroxytriazoles and related compounds as antitubercular agents. French-Ukrainian Journal of Chemistry, 2015, 3, 82-96.	0.4	1
35	Synthesis of 3-heteryl substituted pyrrolidine-2,5-diones via catalytic Michael reaction and evaluation of their inhibitory activity against InhA and <i>Mycobacterium tuberculosis</i> . European Journal of Medicinal Chemistry, 2014, 71, 46-52.	5.5	38
36	Differential Roles of RND Efflux Pumps in Antimicrobial Drug Resistance of Sessile and Planktonic <i>Burkholderia cenocepacia</i> Cells. Antimicrobial Agents and Chemotherapy, 2014, 58, 7424-7429.	3.2	45

#	ARTICLE	IF	CITATIONS
37	Trends in discovery of new drugs for tuberculosis therapy. <i>Journal of Antibiotics</i> , 2014, 67, 655-659.	2.0	43
38	4-Aminoquinolone Piperidine Amides: Noncovalent Inhibitors of DprE1 with Long Residence Time and Potent Antimycobacterial Activity. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 5419-5434.	6.4	97
39	Rv2466c Mediates the Activation of TP053 To Kill Replicating and Non-replicating <i>Mycobacterium tuberculosis</i> . <i>ACS Chemical Biology</i> , 2014, 9, 1567-1575.	3.4	41
40	Synthesis and evaluation of 1,4-ketotriazoles and 1,4,5-trisubstituted-1,2,4-triazoles as inhibitors of <i>Mycobacterium tuberculosis</i> . <i>European Journal of Medicinal Chemistry</i> , 2013, 69, 167-173.	5.5	35
41	Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and <i>Mycobacterium tuberculosis</i> . <i>European Journal of Medicinal Chemistry</i> , 2013, 70, 37-48.	5.5	39
42	DprE1, a new taxonomic marker in mycobacteria. <i>FEMS Microbiology Letters</i> , 2013, 348, 66-73.	1.8	13
43	The DprE1 enzyme, one of the most vulnerable targets of <i>Mycobacterium tuberculosis</i> . <i>Applied Microbiology and Biotechnology</i> , 2013, 97, 8841-8848.	3.6	92
44	A census of RND superfamily proteins in the <i>Burkholderia</i> genus. <i>Future Microbiology</i> , 2013, 8, 923-937.	2.0	15
45	Improved BM212 MmpL3 Inhibitor Analogue Shows Efficacy in Acute Murine Model of Tuberculosis Infection. <i>PLoS ONE</i> , 2013, 8, e56980.	2.5	90
46	Phenotypic and Genotypic Characterisation of <i>Burkholderia cenocepacia</i> J2315 Mutants Affected in Homoserine Lactone and Diffusible Signal Factor-Based Quorum Sensing Systems Suggests Interplay between Both Types of Systems. <i>PLoS ONE</i> , 2013, 8, e55112.	2.5	36
47	MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 324-331.	3.2	190
48	Evaluation of Fluoroquinolone Resistance Mechanisms in <i>Pseudomonas aeruginosa</i> Multidrug Resistance Clinical Isolates. <i>Microbial Drug Resistance</i> , 2012, 18, 23-32.	2.0	31
49	Structural Basis for Benzothiazinone-Mediated Killing of <i>Mycobacterium tuberculosis</i> . <i>Science Translational Medicine</i> , 2012, 4, 150ra121.	12.4	159
50	Benzothiazinones Are Suicide Inhibitors of Mycobacterial Decaprenylphosphoryl- $\beta$ -D-ribofuranose 2-Oxidase DprE1. <i>Journal of the American Chemical Society</i> , 2012, 134, 912-915.	13.7	155
51	Chemical synthesis and biological evaluation of triazole derivatives as inhibitors of InhA and antituberculosis agents. <i>European Journal of Medicinal Chemistry</i> , 2012, 52, 275-283.	5.5	81
52	Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 5524-5531.	5.5	84
53	Deciphering the Role of RND Efflux Transporters in <i>Burkholderia cenocepacia</i> . <i>PLoS ONE</i> , 2011, 6, e18902.	2.5	68
54	Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in <i>Mycobacterium smegmatis</i> . <i>PLoS ONE</i> , 2011, 6, e26675.	2.5	41

#	ARTICLE	IF	CITATIONS
55	Decaprenylphosphoryl- $\beta$ -D-Ribose 2-Epimerase from <i>Mycobacterium tuberculosis</i> is a Magic Drug Target. <i>Current Medicinal Chemistry</i> , 2010, 17, 3099-3108.	2.4	88
56	Exploring the HME and HAE1 efflux systems in the genus <i>Burkholderia</i> . <i>BMC Evolutionary Biology</i> , 2010, 10, 164.	3.2	32
57	Biological and structural characterization of the <i>Mycobacterium smegmatis</i> nitroreductase NfnB, and its role in benzothiazinone resistance. <i>Molecular Microbiology</i> , 2010, 77, 1172-1185.	2.5	63
58	<i>Mycobacterium tuberculosis</i> Phosphoribosylpyrophosphate Synthetase: Biochemical Features of a Crucial Enzyme for Mycobacterial Cell Wall Biosynthesis. <i>PLoS ONE</i> , 2010, 5, e15494.	2.5	19
59	Clinical Isolates of <i>Mycobacterium tuberculosis</i> in Four European Hospitals Are Uniformly Susceptible to Benzothiazinones. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1616-1618.	3.2	90
60	Azole resistance in <i>Mycobacterium tuberculosis</i> is mediated by the MmpS5-MmpL5 efflux system. <i>Tuberculosis</i> , 2009, 89, 84-90.	1.9	161
61	Assessment of three Resistance-Nodulation-Cell Division drug efflux transporters of <i>Burkholderia cenocepacia</i> in intrinsic antibiotic resistance. <i>BMC Microbiology</i> , 2009, 9, 200.	3.3	72
62	Control of MRSA infection and colonisation in an intensive care unit by GeneOhm MRSA assay and culture methods. <i>BMC Infectious Diseases</i> , 2009, 9, 137.	2.9	12
63	<i>Mycobacterium tuberculosis</i> : drug resistance and future perspectives. <i>Future Microbiology</i> , 2009, 4, 597-614.	2.0	68
64	Benzothiazinones Kill <i>Mycobacterium tuberculosis</i> by Blocking Arabinan Synthesis. <i>Science</i> , 2009, 324, 801-804.	12.6	660
65	Genomic analysis of zinc homeostasis in <i>Mycobacterium tuberculosis</i> . <i>FEMS Microbiology Letters</i> , 2008, 287, 1-7.	1.8	37
66	Global Analysis of the <i>Mycobacterium tuberculosis</i> Zur (FurB) Regulon. <i>Journal of Bacteriology</i> , 2007, 189, 730-740.	2.2	238
67	Efflux pump genes of the resistance-nodulation-division family in <i>Burkholderia cenocepacia</i> genome. <i>BMC Microbiology</i> , 2006, 6, 66.	3.3	82
68	LfrR Is a Repressor That Regulates Expression of the Efflux Pump LfrA in <i>Mycobacterium smegmatis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 4044-4052.	3.2	36
69	mmpL7 Gene of <i>Mycobacterium tuberculosis</i> Is Responsible for Isoniazid Efflux in <i>Mycobacterium smegmatis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4775-4777.	3.2	110
70	Glutamine amidotransferase activity of NAD <sup>+</sup> synthetase from <i>Mycobacterium tuberculosis</i> depends on an amino-terminal nitrilase domain. <i>Research in Microbiology</i> , 2005, 156, 173-177.	2.1	17
71	Characterization and Heterologous Expression of the Oxalyl Coenzyme A Decarboxylase Gene from <i>Bifidobacterium lactis</i> . <i>Applied and Environmental Microbiology</i> , 2004, 70, 5066-5073.	3.1	65
72	Rv2686c-Rv2687c-Rv2688c, an ABC Fluoroquinolone Efflux Pump in <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3175-3178.	3.2	148

#	ARTICLE	IF	CITATIONS
73	Fighting Against Resistant Strains: The Case of Benzothiazinones and Dinitrobenzamides. , 0, , .		1
74	The Clitocybins and 2-Substituted-Isoindolin-1-Ones: Synthesis and in Vitro Antimycobacterial Activities. Journal of Advances in Chemistry, 0, 16, 5387-5394.	0.1	1